Amneal Pharmaceuticals, Inc. AMRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenue by Business | ||||||
| Affordable Medicines | $1.75B+2.7% | $1.75B+3.6% | $1.75B+8.3% | $1.71B+10.3% | $1.71B+14.3% | |
| AvKARE | $738.33M+9.8% | $744.73M+12.3% | $704.37M+9.7% | $665.33M+8.3% | $672.7M+17.5% | |
| Other Operating Income by Business | ||||||
| Affordable Medicines | $7.06M+37.8% | $5.24M— | $5.24M+1,741% | $5.12M+800% | $5.12M+500% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Gross Profit by Business | ||||||
| Affordable Medicines | $702.64M+1.2% | $683.92M+1.5% | $711.23M+12.0% | $708.96M+18.8% | $694.6M+22.0% | |
| AvKARE | $157.26M+48.4% | $146.79M+41.7% | $127.57M+23.5% | $113.56M+12.1% | $105.96M+9.6% | |
| Specialty | $317.62M+33.6% | $282.59M+16.3% | $240.19M+16.0% | $252.06M+28.9% | $237.71M+26.4% | |
| Operating Income (Loss) by Business | ||||||
| Affordable Medicines | $390.95M-0.3% | $380.8M+41.0% | $390.7M+58.0% | $393.37M+72.5% | $392.3M+100% | |
| AvKARE | $93.1M+109% | $83.62M+94.9% | $65.54M+47.1% | $51.63M+19.2% | $44.46M+13.0% | |
| SG&A by Business | ||||||
| Affordable Medicines | $149.99M+15.2% | $142.38M+9.9% | $139.03M+10.7% | $132.81M+6.5% | $130.21M+5.8% | |
| AvKARE | $64.16M+4.3% | $63.18M+4.1% | $62.02M+5.5% | $61.93M+6.9% | $61.5M+7.3% | |
| Gain (Loss) from Litigation Settlement by Business | ||||||
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Other by Business | ||||||
| Affordable Medicines | $27.45M-10.5% | $28.41M-6.1% | $28.93M-6.8% | $29.05M-5.6% | $30.68M+4.1% | |
| Specialty | $5.24M+68.5% | $5.58M+115% | $6.09M+104% | $3.9M-4.8% | $3.11M-39.2% | |
| Restructuring and other charges by Business | ||||||
| Affordable Medicines | $2.97M+4,144% | $2.97M+4,144% | $773K+530% | $700K+342% | $70K-55.8% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Currency translation by Business | ||||||
| Affordable Medicines | -$3.7M— | -$1.97M— | -$2.38M— | -$1.13M— | —— | |
| AvKARE | $0— | $0— | $0— | $0— | —— | |
| Specialty | $0— | $0— | $0— | $0— | —— | |
| Product development and studies by Business | ||||||
| Affordable Medicines | $4.05M+234% | $3.45M-8.6% | -$3.8M-165% | -$321K-106% | $1.21M-83.3% | |
| Specialty | $8.97M+172% | $8.52M+505% | $8.44M+590% | $5.58M+179% | $3.29M+23.9% | |
| Regulatory fees by Business | ||||||
| Affordable Medicines | $8.79M+60.3% | $6.4M+16.6% | $8.35M+81.0% | $7.58M+43.3% | $5.49M-17.9% | |
| Specialty | $0— | $0— | $0-100% | $0-100% | $0-100% | |
| Cost of goods sold by Business | ||||||
| Affordable Medicines | $1.05B+3.7% | $1.06B+5.0% | $1.04B+6.0% | $1.01B+5.0% | $1.01B+9.6% | |
| AvKARE | $581.07M+2.5% | $597.94M+6.9% | $576.81M+7.1% | $551.77M+7.5% | $566.74M+19.1% | |
| Materials and supplies by Business | ||||||
| Affordable Medicines | $31.86M-18.6% | $31.57M-22.2% | $38.59M+27.8% | $41.24M+54.6% | $39.15M+50.6% | |
| Specialty | $2.85M+187% | $3M+145% | $2.38M+12.0% | $1.16M-64.4% | $993K-76.7% | |
| R&D by Business | ||||||
| Affordable Medicines | $158.32M-6.0% | $156.01M-9.2% | $176.6M+13.0% | $178.58M+35.1% | $168.38M+26.1% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Affordable Medicines | $639.51M-1.4% | $643.21M-1.0% | $645.18M-0.9% | $647.56M-0.5% | $648.68M-0.5% | |
| AvKARE | $277.86M0.0% | $277.86M0.0% | $277.86M0.0% | $277.86M0.0% | $277.86M0.0% | |
| Specialty | $1.47B0.0% | $1.47B0.0% | $1.47B0.0% | $1.47B0.0% | $1.47B0.0% | |
| Employee compensation and benefits by Business | ||||||
| Affordable Medicines | $53.86M+11.0% | $54.37M+16.8% | $53.43M+13.6% | $50.71M+6.4% | $48.5M+3.2% | |
| Specialty | $44.77M+21.2% | $43.71M+25.2% | $41.49M+18.1% | $38.68M+7.2% | $36.94M+2.3% | |
| Facilities costs by Business | ||||||
| Affordable Medicines | $6.69M+0.5% | $6.83M+1.8% | $6.91M+0.8% | $6.76M-5.2% | $6.66M-8.9% | |
| Specialty | $1.24M-76.8% | $1.96M-66.6% | $3.41M-40.7% | $4.6M-17.5% | $5.36M-2.3% | |
| Milestones by Business | ||||||
| Specialty | $3M0.0% | $6M— | $3M— | $3M— | $3M— | |
| Intellectual property legal development expenses by Business | ||||||
| Affordable Medicines | $7.17M+11.4% | $7.39M+30.0% | $7.98M+69.5% | $7.38M+92.0% | $6.44M+72.1% | |
| AvKARE | $0— | $0— | $0— | $0— | $0— | |
| Specialty | $238K— | $243K— | —— | —— | —— | |
| Net revenue by Product | ||||||
| Auto-Injector | $226.55M+5.4% | $232.8M+11.1% | $231.6M+9.3% | $223.35M+23.2% | $215.04M+31.7% | |
| Biosimilar | $93.99M-26.1% | $100.23M-20.1% | $109.35M+5.8% | $123.02M+38.0% | $127.27M+67.2% | |
| Central nervous system | $349.19M+24.0% | $333.42M+19.0% | $305.26M— | $301.03M— | $281.51M— | |
| Distribution | $392.71M-8.5% | $408.46M-5.9% | $407.3M-4.4% | $412.69M+1.6% | $429.16M+14.8% | |
| Government label | $279.91M+59.8% | $270.11M+68.9% | $230.17M+55.8% | $184.35M+33.0% | $175.15M+32.4% | |
| Hormonal / allergy | $156.66M+15.8% | $154.93M+18.8% | $144.3M— | $138.89M— | $135.25M— | |
| Injectable | $176.39M+6.9% | $161.24M-2.5% | $171.76M+12.3% | $160.56M+10.6% | $165M+16.5% | |
| Institutional | $34.19M-20.3% | $35.38M-17.2% | $37.72M-9.4% | $41.27M-3.6% | $42.9M+7.2% | |
| International | $16.21M+91.5% | $12.13M+35.4% | $10.72M+30.7% | $8.94M+111% | $8.47M+153% | |
| Oral liquid | $61.37M-35.4% | $72.82M-29.6% | $82.7M-22.2% | $88.82M-20.4% | $95.04M-17.5% | |
| Oral solid | $718.53M+2.8% | $726.38M+5.4% | $720.63M+7.7% | $701.38M+4.6% | $699.08M+6.4% | |
| Other dosage forms | $242.61M+12.7% | $252.42M+24.8% | $243.24M+29.2% | $234.23M+28.1% | $215.34M+20.5% | |
| Other therapeutic classes | $47.13M+57.1% | $39.66M+38.6% | $32.36M— | $30.35M— | $30.01M— | |
| Subtotal dosage forms | $1.74B+2.2% | $1.73B+3.4% | $1.74B+8.2% | $1.71B+10.0% | $1.7B+14.0% | |
| Subtotal therapeutic classes | $552.98M+23.8% | $528.01M+20.2% | $481.92M+15.8% | $470.27M+17.6% | $446.76M+13.5% | |
| Transdermal | $218.41M+19.1% | $187.51M+3.6% | $178.18M+2.5% | $174.47M+2.8% | $183.46M+14.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
